Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its target price boosted by equities researchers at Jefferies Financial Group from $75.00 to $128.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside […]

Related Keywords

, Jefferies Financial Group , Praxis Precision Medicines Inc , Sphera Funds Management , Vr Adviser , Praxis Precision Medicines Company Profile , Praxis Precision Medicines , Get Free Report , Financial Group , Precision Medicines , Praxis Precision , Asset Management , Funds Management , State Street Corp , Street Corp , Praxis Precision Medicines Daily ,